David M. Rubin
Managing Director
Medicine
Daktari Diagnostics
United States of America
Biography
David M. Rubin, Ph.D. is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. David has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. David holds board seats at OpGen, Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx. David joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all MRL disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. David joined Merck from Cognia Corporation where he was CEO and President, and helped to build it into one of the pioneer bioinformatics products company. Previously, David was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies. David holds a Ph.D. from Temple University in Molecular Biology and a BA from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University
Research Interest
His research interest in Business and Management
